Velano Vascular news
Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to unde
Vascular access technology pioneer Velano Vascular today revealed that the 2021 Infusion Therapy Standards of Practice, 8th Ed., include its needle free PIVO™ device and evidence of the procedure’s improved performance for inpatient blood draws. Updated every five years and considered the preeminent guidance for infusion therapy, the newly reset standards from the Infusion Nurses Society (INS) cite PIVO’s ability to improve blood sample quality through decrea
SAN FRANCISCO, January 25, 2021 — Vascular access technology pioneer Velano Vascular today revealed that the 2021 Infusion Therapy Standards of Practice, 8th Ed., include its needle free PIVO™ device and evidence of the procedure’s improved performance for inpatient blood draws. Updated every five years and considered the preeminent guidance for infusion therapy, the newly reset standards from the Infusion Nurses Society (INS) cite PIVO’s ability to imp
Vascular access technology pioneer Velano Vascular was today named a Top Impact Company for 2021 by Real Leaders, the world’s first business and sustainable leadership magazine. Velano was recognized alongside such notable brands as Tesla, Beyond Meat, and Patagonia on the 2021 list for its work making hospital stays more humane and less risky for both patients and practitioners.
Through its family of novel vascular access technologies, including the PIVO™ needle-free bloo
Vascular access technology pioneer Velano Vascular this past week made its new streamlined remote training program widely available for hospitals around the nation. Initially developed with existing partners utilizing its PIVO™ needle-free blood draw device in the fight against COVID-19, the platform is now available for additional hospitals and systems in need of streamlined care.
A number of PIVO customers have already embraced an early iterat
Laboratories in an increasing number of U. S. hospitals and healthcare systems are seeing significantly lower hemolysis rates in the blood specimens their staff are collecting with new technology designed for drawing blood with a single-use, sterile device that advances into the vein through a peripheral IV (PIV).
The technology, PIVO (Velano Vascular, San Francisco, Califo
San Francisco medical device company Velano Vascular closed a $25 million second round of financing, bringing its total overall to $50 million. The new capital will go toward expanding its needle-less blood draw device and to developing new technologies.
CEO Eric Stone would not reveal what these new technologies will entail but said they will fall within the company’s m
SAN FRANCISCO, Dec. 17, 2019 (GLOBE NEWSWIRE) — Vascular access technology pioneer Velano Vascular today announced that it has closed the second tranche of a $25 million growth financing that will fuel commercialization and the launch of additional novel inpatient medical device solutions. This new investment builds on an initial tranche closed in the first half of 2019 and brings Velano’s total funding to more than $50 million from a mix of company insiders, venture cap
For most of us, getting blood drawn is an unpleasant, but necessary, part of life. For others, though, it’s extremely risky, if not impossible. Those people have what is known as difficult venous access (DVA), and they can include children, people witjh chronic illnesses, the elderly and people with diabetes, among others.
Velano Vascular is a company that has developed a way to draw blood in the hospital that isn’t invasive; rather than using a needle, Velano&rs